На главную
Результаты поиска “Hormone receptor positive breast cancer therapy”
Hormone Receptor-Positive Breast Cancer
 
02:30
Breastlink founder Dr. Link, author of “The Breast Cancer Survival Manual,” explains why drugs like Tamoxifen and aromatase inhibitors reduce a woman’s risk of developing breast cancer. When researches began sequencing cancer genes in 2003 and 2004, they discovered that cancer wasn’t a homogenous disease. There were variations and they eventually divided cancer into subtypes: triple negative (15% of breast cancer), HER2 amplified type (12-15% of breast cancer), and hormone receptor positive, also known as the luminal cancer (over 70% of breast cancer). Luminal cancer cells have estrogen and progesterone receptors on their surface and have to receive these hormones in order to survive. To prevent these tumors from getting estrogen, doctors prescribe Tamoxifen, which blocks the estrogen receptors and kills the cell. After a woman goes into menopause and her ovaries stop producing estrogen, the tumor can still receive estrogen from the adrenal gland. Aromatase inhibitors are used to block adrenal estrogen. For more information about Breastlink and breast cancer, visit our website: www.breastlink.com
Просмотров: 3993 Breastlink Orange
Hormone Receptor Positive Breast Cancer
 
02:57
All breast tumors are tested to see if they are hormone sensitive. Those tumors that are hormone sensitive will typically respond to anti-estrogen treatments. In this video, you will learn about hormone-sensitive breast cancer.
Просмотров: 2033 Dr. Susan Love Research Foundation
Hormone Receptor-Positive and HER2-Positive Breast Cancer: A Medical Update
 
01:08:15
Featuring Sara Hurvitz, MD, FACP, learn about the use of targeted therapies for early-stage, hormone receptor-positive and HER2-positive breast cancer, explore how these medicines reduce risk of recurrence and how they may be used before and after surgery.
Просмотров: 12418 Living Beyond Breast Cancer
Estrogen Receptor Positive Breast Cancer. ER+. What is it?
 
04:55
ER positive breast cancer means that the cancer cells grow and reproduce fast in response to the hormone estrogen. The diagnosis is based on the results of Immunohistochemistry assay. Assay is used to show whether or not the cancer cells have hormone receptors on their surface. Why is it important? When Estrogen gets attached to the receptor, it’s a signal to our DNA: start to grow and reproduce. (1)The more receptors cancer calls have, the stronger the signal. (2)The more Estrogen there is in the blood stream, the stronger the signal to the DNA. Hormone receptor status is important because oncologist will decide whether the cancer is likely to respond to hormonal therapy. Hormonal therapy includes medications that (1) block estrogen receptor, so Estrogen cannot sit there and send the signal to the DNA: grow and reproduce or (2) lower the amount of estrogen in the body. As a Naturopathic Physician I make sure that my patients do not consume estrogen-like substances. My specialty is: reduction of all types of cancer. Food, water and cosmetics, all should be free of chemicals Stay healthy Dr. V Waks
Просмотров: 2808 Doctor Veronica
Adjuvant Hormonal Therapy for Estrogen Receptor Positive Early Stage Breast Cancer
 
04:54
This video clip will review hormonal therapy options for both pre- and post-menopausal women with estrogen receptor positive, early stage breast cancer. The risks and benefits of Tamoxifen and the Aromatase Inhibitors (anastrozole, letrozole, exemestane) are discussed.
Просмотров: 3350 Mayo Clinic
Breast Cancer Receptors: Learn What You Need to Know
 
08:26
We teach you to about breast cancer tumor receptors and why they are important in your breast cancer treatment. Chemotherapy and hormonal therapy are based on your receptor pattern. VISIT THE BREAST CANCER SCHOOL FOR PATIENTS: http://www.breastcancercourse.org LIST OF QUESTIONS FOR YOUR DOCTORS: http://www.breastcancercourse.org/breast-health-updates-latest-videos/ FOLLOW US: Facebook: https://www.facebook.com/Breast-Cancer-School-for-Patients-958519147618444/ _________________________________ Questions for your Breast Surgeon and Medical Oncologist: 1. What receptors do my tumor have? 2. What type of treatment do they suggest I will need? 3. May I have a copy of all my pathology reports? 4. Do my receptors already suggest I need chemotherapy? 5. Do my receptors show I will need hormonal therapy? 6. Would I benefit from neoadjuvant chemotherapy? What are Breast Cancer Receptors? Once a breast biopsy is determined to be an invasive by a pathologist under the microscope, they will automatically run at least three more tests on the same tissue to determine what “receptors” are present. Receptors are tiny proteins on the surface of the cells that act like “light switches” that can turn cancer cell growth “on” or “off.” The Estrogen receptor (ER), Progesterone receptor (PR), and HER2 receptor results are incredibly important for you to know and understand. Receptors are different than “grade” and “stage” as outlined in the diagram below. All are different pieces of the breast cancer puzzle that your physicians will assemble to determine the best therapy for you. In the case of receptors, these are key determinants as to whether you will or will not benefit from hormonal therapy (pills) or chemotherapy. The receptors involving a precancerous lesion such as DCIS have different implications and are addressed in our DCIS course. Receptors that suggest Hormonal Therapy Estrogen Receptor Positive (ER+) tumors are always treated with hormonal therapy. Usually these types of medications (pills) are taken for a total of 5 to 10 years. It is still possible that one may need chemotherapy in addition to hormonal therapy. If you are Progesterone Receptor Positive (PR+) then you will likely need hormonal therapy, even if you are ER-. The Estrogen Receptor plays a much more important role in cancer care than the Progesterone Receptor. Receptors that suggest Chemotherapy Determining if you need chemotherapy is a very complex decision process and is primarily driven by your medical oncologist. Your “receptor pattern” is a key piece of information that is known early in your breast cancer journey. In about 30% of patients with an invasive breast cancer, the receptor pattern alone can strongly suggest that chemotherapy will be needed, regardless of what is found at surgery. We list a few of the more common “chemotherapy receptor patterns” below. Many factors, including a large cancer and cancer that is present in the lymph nodes, also point someone towards chemotherapy. Take our video lesson on “Will I Need Chemotherapy“ (here). Often if someone needs chemotherapy, they will likely benefit also from hormonal therapy after chemotherapy if their estrogen receptor is positive. Estrogen Receptor Negative (ER-) tumors do not respond to anti-estrogen oral medications that are essential for treating estrogen receptor positive (ER+) tumors. Quite simply, patients with ER negative tumors will benefit from chemotherapy if they are healthy enough to tolerate it. ER negative tumors are more aggressive cancers, but respond very well to chemotherapy. This includes “triple negative” breast cancers. Progesterone Receptors (PR) play a much smaller role than estrogen or HER2 receptors and are not addressed here. HER2 Receptor Positive (HER2+) tumors are very responsive to chemotherapy when paired with new breakthrough drugs that target these tumors, such as Herceptin and Perjeta. The same holds true if a HER2-positive tumor is also ER positive. Take our “HER2-Positive“ video lesson to learn more (here). HER2-positive tumors are more aggressive cancers, but we now can treat them more effectively with chemotherapy and “targeted immunotherapy” drugs that are designed to destroy HER2-positive cancers. “Triple Negative” (ER-)(PR-)(HER2-) tumors are also fast growing tumors that are usually treated with a specific chemotherapy regimen. These tumors are not responsive to hormonal therapy at all, but are sensitive to chemotherapy. If you have “Triple Negative Breast Cancer“ review our video lesson (here). Take home message: Make sure to ask for a copy of the pathology report from your biopsy. Ask your breast surgeon and medical oncologist to explain to you what your receptors mean regarding your treatment. Sometimes the HER2 receptor results can take up to two weeks to become finalized. Inquire early on with your physicians about your benefit from hormonal therapy and/or chemotherapy.
Просмотров: 243 Breast Cancer School for Patients
Advancements in Estrogen Receptor–Positive Breast Cancer
 
09:47
Ingrid A. Mayer, MD, MSCI, and Hope S. Rugo, MD, discuss the role of targeted therapies in the treatment of estrogen receptor–positive breast cancer.
Просмотров: 3551 OncLiveTV
Adjuvant Therapy in Early-Stage ER-Positive, HER2-Negative Invasive Breast Cancer
 
10:59
Dr. Hope Rugo shares her experience on the recommended treatment approach for ER-positive, HER2-negative breast cancer patients. She comments on what is the expected benefit of adjuvant chemotherapy and endocrine therapy in luminal breast cancers and mentions that one of the greatest challenges is to understand the heterogeneity of the tumor. She also provides interesting comments on the use of criteria like tumor grade and size to select the patients for adjuvant chemotherapy as well as the usage of IHC markers such hormone receptors ER-positive, PR and Growth Factor Receptor HER2 to identify patients for chemotherapy. Finally, she speaks about tools such Adjuvant! Online and Predict and debates if these tools could be used to select luminal breast cancer patients confidently for adjuvant chemotherapy. _______________________________________________________ Hope Rugo, MD, is the Clinical Professor, Department of Medicine (Hematology/Oncology); and Director, Breast Oncology and Clinical Trials Education at the University of California San Francisco Helen Diller Family Comprehensive Cancer Center.
Просмотров: 8119 Genomic Health, Inc.
Advanced Hormone Receptor-positive Breast Cancer
 
20:13
Filmed on location in Las Vegas during the 21st Annual NOCR Meeting, this webcast is part of a series that provides expert discussions from physicians and researchers from around the USA reviewing current standards of management and analyzing the most important new data that has the potential to modify treatment guidelines. In this presentation, Dr. William Gradishar expounds upon the latest updates in the treatment of advanced hormone receptor-positive breast cancer. © 2015 Imedex, LLC.
Просмотров: 291 ImedexCME
Hormonal Therapy for Breast Cancer: We Teach You
 
13:39
We teach you about hormonal therapy for breast cancer. Drugs such as tamoxifen and aromatase inhibitors are key treatment options for most breast cancers. VISIT THE BREAST CANCER SCHOOL FOR PATIENTS: http://www.breastcancercourse.org LIST OF QUESTIONS FOR YOUR DOCTORS: http://www.breastcancercourse.org/breast-health-updates-latest-videos/ FOLLOW US: Facebook: https://www.facebook.com/Breast-Cancer-School-for-Patients-958519147618444/ ________________________________ Questions for your Medical Oncologist: 1. What type of hormonal therapy do you recommend? 2. Will I also benefit from chemotherapy? 3. What are the side effects of hormonal therapy? 4. Will I need 5 or 10 years of these medications? 5. Would the genomic assay Oncotype DX be helpful? 6. What is Hormonal Therapy? Anti-estrogen (estrogen-blocking) medications, prescribed as pills, are incredibly effective at treating certain types of breast cancer. Hormonal therapy is given to about 70 to 80% of women with breast cancer. Chemotherapy, on the other hand, is a more intense cancer treatment that is generally administered intravenously. Most patients will not need chemotherapy. Many women that do need chemotherapy will also benefit from hormonal therapy. These treatment decisions are complex ones with your medical oncologist. You will make better choices when you are well informed before meeting with your medical oncologist. Do my “Receptors” suggest Hormonal Therapy? When the estrogen circulating in your blood stream interacts with a breast cancer that has “Estrogen Receptors” (ER) present on its surface, it tends to flip the ER switch to the “on” or “grow” position for ER Positive tumors. The same can be said to a lesser extent for the “Progesterone Receptor,” if your cancer is found to also be PR positive. Patients with ER+ breast cancers almost always benefit from the anti-estrogen effects of hormonal therapy. These medications can make cancer cells die, or slow down their growth. If a few cancer cells have already spread to other parts of the body, these medications are incredibly effective at preventing these cells from growing and threatening your life in the future. In other words, those who take hormonal therapy for ER+ tumors have a more successful chance at long-term survival when compared to those who do not. About 80% of all breast cancers are ER+. Even if your medical oncologist recommends chemotherapy for you, if your tumor is ER+ you will also benefit from up to 10 years of hormonal therapy after chemotherapy. Hormonal therapy is never given during chemotherapy nor during radiation therapy. What is “Tamoxifen?” Tamoxifen is an anti-estrogen medication (pills) that has been used with great success with ER+ cancers for three decades. It is now the primary hormonal therapy for younger, pre-menopausal women. It is also the primary drug for men with breast cancer. It is used for some post-menopausal women. What are “Aromatase Inhibitors?” Aromatase inhibitors (AIs) are a class of anti-estrogen medications (pills) that have proven to be slightly more effective than Tamoxifen for post-menopausal women. It is not recommended for younger, pre-menopausal women, except in certain circumstances. The three most common versions are Anastrozole (Arimidex), Letrozole (Femara), and Exemestane (Aromasin). What are the side effects of Hormonal Therapy? Side effects vary greatly from one person to the next for both types of hormonal medications. Some have no symptoms at all. Most have very tolerable side effects. Some patients will need to change hormonal therapy medications to find the best balance of cancer benefit versus side effects. Several side effects that are rather common for both tamoxifen and aromatase inhibitors are hot flashes, night sweats, joint pain, and vaginal dryness. Below, we list some of the other specific side effects for both drugs. Tamoxifen Side Effects: Increased risk of uterine (endometrial) cancer Increased risk of developing blood clots Slows normal bone loss in most women (a “good” side effect) Cannot be taken during pregnancy because of risk of birth defects or fetal death Can temporarily induce menopause in pre-menopausal women. Aromatase Inhibitor Side Effects: Can worsen bone loss (osteoporosis) in women Muscle and joint aches and pains Would an “Oncotype DX” assay help me? Patients who have a small, estrogen receptor positive, HER2 receptor negative tumor, and no evidence of cancer in their lymph nodes may benefit from an Oncotype DX genomic assay. This cutting-edge test looks deeper into your cancer cells to better identify people who may also benefit from chemotherapy with ER+ breast cancers. The decision to undergo chemotherapy, in addition to hormonal therapy, is a complicated one. Your medical oncologist uses many factors to help decide if you will benefit from chemotherapy. An Oncotype DX analysis of a portion of your breast cancer tissue can be instrumental in this decision.
Просмотров: 379 Breast Cancer School for Patients
Anastrozole and Fulvestrant in Hormone Receptor-Positive Breast Cancer
 
05:50
A commentary by Dr. William J. Gradishar and Dr. Hope S. Rugo on fulvestrant and anastrozole as first-line therapy in hormone receptor-positive breast cancer
Просмотров: 954 MDedge
A Discussion on Hormone Receptor-Positive Breast Cancer and the Latest in Surgical Management
 
01:15:31
The Breast Cancer Issues Conference is a place to discuss topics covering the latest in breast cancer research and treatment, risk reduction and quality of life issues with leading researchers and experts. Brought to you by Susan G. Komen Oregon and SW Washington.
Просмотров: 50 Susan G. Komen Oregon & SW Washington
Risk Stratification of Patients with Hormone-Receptor Positive Breast Cancer
 
02:51
Peter Schmid, Professor of Cancer Medicine and Clinical Director of the St. Bartholomew Breast Cancer Centre, UK, explores how risk stratification is performed in clinical practice and how treatment strategies are decided for patients with hormone-receptor positive breast cancer. Q1. How is risk stratification performed in clinical practice, and how do you decide if a patient with hormone-receptor positive breast cancer is suited for endocrine monotherapy, targeted combination therapy or chemotherapy? Q2. How can this decision-making process be made less subjective in the future? Support: This video was supported by AstraZeneca.
Просмотров: 24 Touch Medical Media
Hormone Receptor-Positive Advanced Breast Cancer: Challenges and New Treatment Options
 
01:25:42
This webcast provides expert insight on management strategies for patients with HR-positive breast cancer. Over a review of several cases, the faculty will provide their assessments, as well as additional details on current abemaclib, ribociclib, palbociclib, and faslodex studies, everolimus and NSABP B 42, breast cancer index and other biomarkers. The webcast is moderated by Dr. Jame Abraham of the Cleveland Clinic. Visit http://www.ccfcme.org/tumorboard to claim CME credit or learn more about the Biologic Therapies VII series. Interested in related CME education? Visit http://www.ccfcme.org
Просмотров: 103 ClevelandClinicCME
Hormone Receptor Positive Disease: New Developments
 
35:27
Lecture by Martine J. Piccart-Gebhart, M.D., Ph.D. This podcast highlights important outstanding issues with respect to hormone receptor positive disease, including clinical thresholds for considering chemotherapy, opportunities to further tailor endocrine therapy, distinguishing characteristics of luminal A and luminal B tumors, and novel tumor markers.
Просмотров: 872 TheOncologistJournal
Treatment Overview: ER-positive Breast Cancer
 
04:10
Adam M. Brufsky, MD, PhD, and Lynn Acierno, BSN, RN, OCN, RN-BC, discuss common considerations of patients and their healthcare professionals in the treatment of hormone receptor positive breast cancers. View more at http://curetoday.com/ CURE: Combining science and humanity to make cancer understandable.
Просмотров: 36 curetoday
Latest Estrogen Receptor Positive Breast Cancer Information
 
25:15
This power point presentation was given by Dr. Joe Veltmann on August 28th in Guadalajara, Mexico before 200+ medical doctors who heard Dr. Bernard Esquivel speak about pharmacogenomics and Dr. Veltmann about the ER + breast cancer research and how nutrigenomics may play a role in preventing its recurrence.
Просмотров: 1659 Joe Veltmann
Treatment Strategies in ER-Positive Breast Cancer
 
01:36
Adam Brufsky, MD, discusses tamoxifen therapy and the use of genomic assays in estrogen-receptor positive metastatic breast cancer. For more expert insight, visit http://www.onclive.com/insights/evolution-metastatic-breast-cancer
Просмотров: 367 OncLiveTV
Hormonal therapy in breast cancer
 
20:17
This video describes therapy with anti-estrogens medications in breast cancer.
Просмотров: 23565 charlottecancer
HER2 Positive Breast Cancer: Everything You Must Know
 
13:08
We teach you why HER2-positive breast cancers are more threatening and educate you about new therapies such as targeted immunotherapy and neoadjuvant chemotherapy. VISIT THE BREAST CANCER SCHOOL FOR PATIENTS: http://www.breastcancercourse.org LIST OF QUESTIONS FOR YOUR DOCTORS: http://www.breastcancercourse.org/breast-health-updates-latest-videos/ FOLLOW US: Facebook: https://www.facebook.com/Breast-Cancer-School-for-Patients-958519147618444/ _____________________________ Questions for your Breast Surgeon and Medical Oncologist: 1. What is HER2-Positive breast cancer? 2. Will I need Chemo and Targeted Therapy? 3. What are the benefits of Neoadjuvant Chemo? 4. Isn’t Neoadjuvant Chemo recommended more now? 5. Should I consider a Clinical Trial? 6. What is “HER2-Positive” breast cancer? “HER2-Positive” breast cancers are fast growing tumors that more frequently spread beyond the breast to other parts of the body. Because of this, they are a bigger threat to your life than most other types of cancers with different receptor patterns. These cancers are called “HER2-positive” because they have too many HER2 protein receptors on their surface. These tiny proteins act like “light switches” to turn cancer cell growth “on.” Chemotherapy, combined with new, “targeted” drugs, are very effective against HER2-positive breast cancer and are a leap forward in breast cancer care. Your Breast Surgeon will know your “receptor pattern” within days after your initial breast biopsy. These results are often not communicated to you early on in your decision process. Although only 20% of breast cancers are “HER2-positive,” it is imperative that you specifically ask your surgeon immediately, and well before surgery, “What are my receptor results?” Take our lesson on “My Tumor Receptors” to learn more. Treated with Chemo and “Targeted Therapy” HER2 Receptor Positive (HER2+) tumors are incredibly responsive to chemotherapy when paired with new breakthrough drugs that target these cancers, such as Herceptin and Perjeta. The same holds true if a HER2+ tumor is also Estrogen Receptor positive (ER+). HER2+ tumors are more aggressive cancers, but we now can treat them more effectively, than in the past, with chemotherapy and “targeted immunotherapy” drugs that are designed to destroy them. Everyone with a HER2+ tumor larger than 5mm (1/4 inch) and in good health is considered for chemotherapy and targeted therapy. Unfortunately, studies have shown that many patients are not offered these standard of care, life-saving “targeted drugs” along with chemotherapy. You will make better treatment choices when you are well informed about HER2 therapies before meeting with your medical oncologist. You must inquire about Herceptin, Perjeta, and other “anti-HER2 drugs” that may be of benefit to you. Ask about the benefits of “Neoadjuvant Chemo” What is often overlooked are the benefits of offering neoadjuvant chemotherapy for patients with HER2-Positive, “Early-Stage” (1 & 2) breast cancers. There are distinct advantages (listed below) to having chemotherapy before surgery instead of afterwards. The decision to consider neoadjuvant chemotherapy always begins with your breast surgeon. Breast surgeons choose the initial direction of your entire breast cancer treatment plan. You must address this “cutting edge” treatment option well before surgery to benefit from neoadjuvant chemotherapy. Do not be afraid to ask. This is a very important question. Learn more about “Neoadjuvant Chemotherapy“ by taking our video lesson on the topic. The Potential Benefits of Neoadjuvant Chemo: *Begin life-saving chemotherapy earlier *Reduce the need for a mastectomy *Improve lumpectomy cosmetic outcomes *Reduce the need for an “Axillary Dissection” *Allows more time for BRCA genetic testing *More time to think about “lumpectomy vs. mastectomy” *Shows your cancer team if the chemo is working *Can possibly eliminate all cancer cells before surgery *Reduces the need for radiation after a mastectomy Ask if you might benefit from a Clinical Trial. New therapies must be studied in clinical trials to make sure they are safe and effective at treating breast cancer. HER2-positive breast cancers are currently the focus of intense clinical research. New drug treatments are rapidly being developed for this aggressive cancer. Less than 5% of all patients with breast cancer participate in clinical trials. Patients with cancer willing to participate in clinical trials are essential for the advancement of breast cancer care. Ask your medical oncologist if they offer or recommend you participate in a clinical trial for your unique breast cancer situation. Learn more about “Clinicial Trials“ at the Breast Cancer School for Patients.
Просмотров: 4862 Breast Cancer School for Patients
Treatment of ER+ Breast Cancer
 
03:49
SERM = SELECTIVE estrogen receptor modulator, not "SPECIFIC" estrogen receptor modulator, which is what i said in this video. Sorry for the confusion!
Просмотров: 863 YT Productions
Novel targeted drug palbociclib slows progression of hormone receptor-positive breast cancer
 
03:20
Visit http://www.ecancer.org for more Dr Turner (The Institute of Cancer Research, London, UK) talks to ecancertv at ASCO 2015 about the phase III registration study PALOMA-3, which reports that adding the investigational targeted agent palbociclib to standard hormonal therapy (fulvestrant) more than doubled the duration of disease control, delaying disease progression by roughly five months in women with previously treated, hormone receptor-positive, human epidermal growth factor receptor 2 negative (HR /HER2-) advanced breast cancer.
Просмотров: 69 ecancer
Novel targeted drug palbociclib slows progression of hormone receptor-positive breast cancer
 
03:34
Visit http://www.ecancer.org for more Dr Turner (The Institute of Cancer Research, London, UK) presents, at a press conference at ASCO 2015, the phase III registration study PALOMA-3, which reports that adding the investigational targeted agent palbociclib to standard hormonal therapy (fulvestrant) more than doubled the duration of disease control, delaying disease progression by roughly five months in women with previously treated, hormone receptor-positive, human epidermal growth factor receptor 2 negative (HR /HER2-) advanced breast cancer.
Просмотров: 38 ecancer
Hormone Positive (ER+/PR) MBC - Dr. Katie Reeder Hayes - 2014 MBCN Conference at UNC
 
44:43
Current diagnosis, treatment and management of Hormone sensitive metastatic breast cancer also called ER+/PR+ or ER+/PR- disease.
Просмотров: 1266 Metastatic Breast Cancer Network (MBCN)
Hormone Receptor Positive, HER2- Breast Cancer Clinical Trial
 
04:25
A Single Arm Phase II Study of Palbociclib in Combination with Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer: Big Ten Cancer Research Consortium BTCRC-BRE15-016. http://www.bigtencrc.org
Просмотров: 235 Big Ten Cancer Research Consortium
Treatment for Early-Stage ER+ Breast Cancer
 
07:04
Hope S. Rugo, MD, and Ruth O’Regan, MD, discuss adjuvant and neoadjuvant endocrine therapy as treatment for early-stage estrogen receptor(ER)–positive breast cancer.
Просмотров: 436 OncLiveTV
Adjuvant Therapy for ER+/HER2+ Breast Cancer
 
06:34
Panelists Michael Untch, MD; Adam M. Brufsky, MD, PhD; Hope S. Rugo, MD; and Joyce A. O’Shaughnessy, MD, discuss sequencing of a HER2-targeted TKI and HER2-targeted monoclonal antibody, and lessons learned from the GeparQuinto and ExteNET trials in ER-positive HER2-positive breast cancer.
Просмотров: 299 OncLiveTV
Will I need Chemotherapy for My Breast Cancer?
 
14:48
We teach you how your tumor receptors, lymph nodes, genomic assays, and breast cancer stage indicates if you would benefit from chemotherapy. VISIT THE BREAST CANCER SCHOOL FOR PATIENTS: http://www.breastcancercourse.org LIST OF QUESTIONS FOR YOUR DOCTORS: http://www.breastcancercourse.org/breast-health-updates-latest-videos/ FOLLOW US: Facebook: https://www.facebook.com/Breast-Cancer-School-for-Patients-958519147618444/ ____________________________________ Questions for your Medical Oncologist and Breast Surgeon: 1. Would I benefit from chemotherapy? 2. What factors suggest I will benefit from chemotherapy? 3. What is the risk to my life if I do not undergo chemotherapy? 4. What are the advantages of “Neoadjuvant Chemo” before surgery? 5. Would a “Genomic Assay” help determine if I need chemotherapy? 6. What is chemotherapy? Chemotherapy is the use of certain medications to treat cancer systemically, meaning throughout the whole body. If needed, chemotherapy is usually given after surgery for invasive breast cancer. It is a more intense cancer treatment than hormonal therapy (usually pills). Only a minority of breast cancer patients will ever need it. These complex decisions are ones you will make with your medical oncologist. You will make better treatment choices when you are informed about chemotherapy and hormonal therapy before meeting with your medical oncologist. General indications for chemotherapy We outline below some of the more common indications for needing chemotherapy. The decision to undergo chemotherapy also involves being healthy enough to tolerate the treatment. Deciding who needs chemotherapy and what type of chemotherapy to administer is one of the most difficult decisions made in medicine. Your medical oncologist will guide you. Do my “receptors” suggest I need chemotherapy? Once a breast biopsy is found to be cancerous, the pathologists will automatically run more tests on the same tissue to determine what “receptors” are expressed. Your receptor pattern is a key piece of information that comes early in your breast cancer journey. In about 30% of patients with an invasive breast cancer, the receptor pattern alone can strongly suggest that chemotherapy will be needed regardless of what is found at surgery. The key points regarding receptors are outlined below. Estrogen Receptor Negative (ER -) tumors (20%) do not respond to anti-estrogen oral medications that are essential in treating estrogen receptor positive (ER +) tumors. Quite simply, patients with ER negative tumors will benefit from chemotherapy if they are healthy enough to tolerate it. ER negative tumors are more aggressive cancers, but respond more favorably to chemotherapy than ER positive breast cancers. HER2 Receptor Positive (HER2+) tumors (20%) are very responsive to chemotherapy when paired with new breakthrough drugs that target these tumors, such as Herceptin and Perjeta. The same holds true even if a HER2-positive tumor is also Estrogen Receptor positive (ER+). HER2+ tumors are more aggressive cancers, but we now can treat them more effectively with chemotherapy and new drugs that are “targeted” to destroy HER2-positive cancers. “Triple Negative” (ER-)(PR-)(HER2-) tumors are fast growing tumors that are usually treated with a specific chemotherapy regimen. These tumors are not responsive to hormonal therapy at all, but may be sensitive to chemotherapy. What if cancer is detected in the lymph nodes? If you have “lymph node positive” breast cancer, it is likely you will be offered chemotherapy. Premenopausal women and those with multiple “positive” lymph nodes generally benefit from chemotherapy. If your breast surgeon detects cancer in your lymph nodes before surgery, there may be specific advantages to undergoing “neoadjuvant chemotherapy.” “Inflammatory Breast Cancer” requires chemotherapy If you have been diagnosed with inflammatory breast cancer, the first step is neoadjuvant chemotherapy before surgery. This type of cancer has a high likelihood of spreading to the lymph nodes and other parts of the body. Starting chemotherapy as soon as possible is essential to treating this aggressive breast cancer. A mastectomy is performed after chemotherapy, followed by radiation to the area of the mastectomy to lessen the chance of cancer growing back in that area. What are the advantages of “neoadjuvant chemotherapy”? Neoadjuvant chemotherapy is when chemotherapy is given before surgery, not afterwards. There are specific advantages to neoadjuvant chemotherapy in appropriately selected patients. How can a genomic “Oncotype DX” test be helpful? Patients who have a small, estrogen receptor positive, HER2 receptor negative tumor and no evidence of cancer in their lymph nodes may benefit from an Oncotype DX genomic assay. This cutting-edge test looks deeper into breast cancer cells to better identify people who may benefit from chemotherapy with ER+, HER2 – breast cancers.
Просмотров: 792 Breast Cancer School for Patients
Overcoming Resistance in ER+ Breast Cancer
 
03:35
Massimo Cristofanilli, MD, professor of medicine, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, discusses overcoming resistance to endocrine therapy in ER+ breast cancer.
Просмотров: 218 Targeted Oncology
Dr. Tripathy on the Use of Tamoxifen in  Hormone Receptor-Positive Breast Cancers
 
02:48
Debu Tripathy, MD, Co-Leader, Women's Cancer Program, Norris Comprehensive Cancer Center, University of Southern California, comments on the extended use of tamoxifen in patients with hormone receptor-positive breast cancers. For more targeted therapy resources and information: http://targetedhc.com/
Просмотров: 145 Targeted Oncology
ER+/HER2+ Metastatic Breast Cancer
 
03:19
Hope S. Rugo, MD, looks at the use of CDK4/6 inhibitors for patients with metastatic ER-positive, HER2-positive breast cancer and the trials evaluating their use in this setting.
Просмотров: 555 OncLiveTV
Breast Cancer | Dr. Tony Talebi discusses "Estrogen Receptor Positive Breast Cancer".
 
12:59
Dr. Tony Talebi discusses Estrogen Receptor Positive Breast Cancer with Dr. Lippman. For further discussion please visit http://www.HemOnc101.com Breast cancer is the most common female cancer in the US. Important risk factors for breast cancer are age, gender, reproductive history, hormonal factors, and family history. Although a family history of breast and/or ovarian cancer is common in patients diagnosed with breast cancer, less than ten percent of all breast cancers are associated with genetic mutations. Assay of hormone receptors (estrogen [ER] and progesterone [PR] receptors) is an important component of the pathologic evaluation of breast cancer, for both prognostic and predictive purposes, as patients with hormone receptor-positive tumors benefit from the addition of endocrine treatments. The treatment of early stage breast cancer includes the treatment of locoregional disease with surgery, radiation therapy, or both, and the treatment of systemic disease with one or a combination of chemotherapy, endocrine therapy, or biologic therapy. Here, Dr. Tony Talebi discusses the general concepts of what is estrogen receptor positive breast cancer with world renowned breast cancer expert Dr. Marc Lippman, professor and chairman of the department of medicine at the University of Miami. Dr. Marc Lippman pioneered the use of tamoxifen in estrogen receptor positive breast cancer with his early research while at the National Cancer Institute which revolutionized the treatment of breast cancer. The discussion includes symptoms, diagnosis, staging, genetic implications, surgery, radiation therapy, Oncotype DX testing, hormonal therapy including tamoxifen and aromatase inhibitors and chemotherapy for breast cancer. Dr. Marc Lippman credentials: Certifications American Board of Internal Med-Medical Oncology American Board of Internal Medicine American Bd of Int Med-Endocrinology Diabetes & Metabolism Specialties Hematology/Oncology - Internal Medicine Internal Medicine Roles Interim Deputy Director, Sylvester Comprehensive Cancer Center Professor and Chairman Biography Marc E. Lippman, M.D. was named the Kathleen and Stanley Glaser Professor of Medicine at the University of Miami Leonard M. Miller School of Medicine, and was named Chairman of the Department of Medicine in May 2007. Previously Dr. Lippman was the John G. Searle Professor and Chair of Internal Medicine at the University of Michigan, Ann Arbor, Michigan. From 1988 through 1999 Dr. Lippman was Professor of Medicine and Pharmacology, and Chair, Department of Oncology at Georgetown University in Washington, D.C., and served as Director of the Lombardi Cancer Center at Georgetown University Medical Center. From 1978 through 1990 he was Clinical Professor of Medicine and Pharmacology, Uniformed Services, University of the Health Sciences. Dr. Lippman served as Head of the Medical Breast Cancer Section, Medicine Branch, at the National Institute of Health. He was a Senior Investigator at the National Cancer Institute of the National Institute of Health. Dr. Lippman completed a Fellowship in Endocrinology at Yale Medical School in New Haven, CT from 1973-1974. In addition, he was Clinical Associate at the National Cancer Institute from 1970-1971 and Clinical Associate at the Laboratory of Biochemistry of the National Cancer Institute of the National Institute of Health. From 1970 to 1988 he served as an Officer and Medical Director of the United States Public Health Service. Dr. Lippman completed his residency on the Osler Medical Service, John Hopkins Hospital, in Baltimore, Maryland from 1968-1970. A native of New York, Dr. Lippman received his Bachelor's Degree from Cornell University, Magna Cum Laude, and medical school degree at Yale Medical School in New Haven, CT where he was elected to AOA. Dr. Lippman is widely known for his research in breast cancer. Throughout his illustrious career he has received numerous awards including Mallinckrodt Award of the Clinical Radioassay Society in 1978; the Commendation Medal USPHS in 1982; Meritorius Service Medal, USPHS in 1987; Clinical Investigator Award, American Federation for Clinical Research in 1985; D.R. Edwards Lecture and Medal, Tenovus Institute, Wales 1985; Plenary Lecturer, British Association of Cancer Research in 1987; Gosse Lecture, Dalhuosie University, Halifax Nova Scotia in 1987; the American Cancer Society.
Просмотров: 2137 Tony Talebi
BREAST CANCER: ESTROGEN RECEPTORS
 
02:06
BREAST CANCER: ESTROGEN RECEPTORS
Просмотров: 7238 Walter Jahn
Adjuvant therapy for early stage ER-positive, HER2-negative invasive breast cancer
 
11:07
Hope S. Rugo, MD, of UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, shares her experience on the recommended treatment approach for oestrogen receptor (ER)-positive, HER2-negative breast cancer patients. Prof Rugo comments on the expected benefit of adjuvant chemotherapy and endocrine therapy in luminal breast cancers and mentions that one of the greatest challenges is to understand the heterogeneity of the tumour. She also comments on the use of criteria, such as tumour grade and size, to select patients for adjuvant chemotherapy as well as the usage of immunohistochemistry (IHC) markers, such as hormone receptor markers, to identify patients for chemotherapy. Finally, she speaks about tools, such as Adjuvant! Online and Predict, and debates if these tools could be used to select luminal breast cancer patients confidently for adjuvant chemotherapy. This content is supported by Genomic Health, Inc.
Просмотров: 415 European Medical Group
Anti-Estrogen Therapy and Breast Cancer Recurrence
 
01:06
http://www.dailyrxnews.com/extending-anti-estrogen-therapy-reduced-breast-cancer-recurrence-massachusetts-general-hospital After fighting through chemotherapy, radiation or other treatments, the recurrence of cancer can be a bummer. But a new approach to hormone therapies might give doctors and patients a leg up. Research presented at the American Society of Clinical Medicine indicated that extending the length of anti-estrogen hormone therapy decreased the risk of breast cancer recurrence. A type of breast cancer known as hormone receptor-positive breast cancer is driven by the hormones estrogen, progesterone or both. As part of the treatment, women with this kind of breast cancer typically receive medications called aromatase inhibitors, which help reduce levels of estrogen. Many patients also receive a medication called tamoxifen which also reduces estrogen.
Просмотров: 433 dailyRx
Ribociclib improves PFS for postmenopausal women with hormone receptor-positive breast cancer
 
03:09
Dr Hortobagyi talks to ecancertv at ESMO 2016 about how the addition of the CDK4/6 inhibitor ribociclib to letrozole therapy significantly improved progression-free survival in postmenopausal women with hormone receptor-positive advanced breast cancer.
Просмотров: 177 ecancer
Breast Cancer Pathogenesis
 
04:40
Breast cancer is the most common cancer worldwide, and the second leading cause of cancer death.Breast cancer cells have receptors on their surface and in their cytoplasm and nucleus. Chemical messengers such as hormones bind to receptors, and this causes changes in the cell. Breast cancer cells may or may not have three important receptors: estrogen receptor (ER), progesterone receptor (PR), and HER2. ER+ cancer cells depend on estrogen for their growth. Untreated, HER2+ breast cancers are generally more aggressive than HER2- breast cancers. Cells that do not have any of these three receptor types are called triple-negative, although they frequently do express receptors for other hormones, such as androgen receptor and prolactin receptor. It is important to understand the aetio-pathogenesis of this common disease, which is associated with high morbidity and mortality, especially if not detected early. Therefore, the roles of early screening in high risk or susceptible individuals, as well as proper surveillance of treated cases in order to detect recurrence at the early stages have been advocated.
Просмотров: 5537 Proteinlounge
Heterogeneity of Metastatic HR+ Breast Cancer
 
02:51
Expert Joyce O’Shaughnessy, MD, describes the heterogeneity of patients with metastatic hormone receptor-positive breast cancer regarding sensitivity to endocrine therapy and aggressiveness of the disease.
Просмотров: 89 OncLiveTV
Neoadjuvant Therapy for HR+ Breast Cancer
 
09:36
Adam M. Brufsky, MD, PhD, FACP; Lee Schwartzberg, MD, FACP; Komal Jhaveri, MD, FACP; Hope S. Rugo, MD; and Francisco Esteva, MD, PhD, describe the case of a patient with unresectable hormone receptor–positive breast cancer to determine whether she should receive neoadjuvant therapy with a CDK4/6 inhibitor and endocrine therapy or chemotherapy.
Просмотров: 304 OncLiveTV
First-Line ER-Positive Metastatic Breast Cancer Treatments
 
05:32
Joanne Blum, MD, PhD, Adam Brufsky, MD, PhD, and Harold J. Burstein, MD, PhD, discuss the first-line treatment of estrogen receptor-positive metastatic breast cancer. For more expert insight, visit http://www.onclive.com/insights/evolution-metastatic-breast-cancer
Просмотров: 340 OncLiveTV
Jason S. Carroll - Understanding estrogen receptor transcription in breast cancer
 
29:20
SfE BES 2016, Brighton, Plenary Lecture 1
Просмотров: 1121 Society for Endocrinology
Estrogen Receptor Positive (ER+) Breast Cancer Outlook 2017 Industry Growth Analysis
 
00:44
This latest “Estrogen Receptor Positive (ER+) Breast Cancer - Treatment Landscape & Competitive Analysis, 2017” report provides comprehensive insights about the treatment landscape across this indication. This report also provides the deep understanding of the stages of the Estrogen Receptor Positive (ER+) Breast Cancer, epidemiology, risk factors, diagnosis etc. A key objective of the report is to establish the understanding of the treatment landscape and competitive analysis of the Estrogen Receptor Positive (ER+) Breast Cancer which mainly describes the treatment of breast cancer at different stages.
Просмотров: 16 sheakhar ibhad
SABCS: Debu Tripathy Discusses Hormonal Therapy Advances in Breast Cancer
 
02:34
Debu Tripathy reports on recent studies involving hormone therapy in estrogen receptor-positive breast cancer. Two trials, called SOFT and TEXT were combined and long-term follow up results were announced at the San Antonio Breast Cancer Symposium. In the combined results, certain groups of patients, but not all, did seem to receive a benefit with tamoxifen in addition to shutting down the ovaries. "This is an important conversation for patients to have when they are completing their therapy if their tumor is hormone-sensitive, and they're going to be getting hormone therapy and they're pre-menopausal (they're still having their periods)," he says. "For some patients, this may help."
Просмотров: 382 curetoday
2018 Conference on Metastatic Breast Cancer Opening Keynote
 
01:31:31
Saturday Morning, April 20, Keynote Speech for our 2018 Conference on Metastatic Breast Cancer. "Today's Research: Open Clinical Trials and Recent Findings" from Virgina F. Borges, MD, MMSc "Findings from the Bench: the Future of Metastatic Breast Cancer Care" from Suzanne A. W. Fuqua, PhD In the first of this two-part talk, Dr. Borges will speak about how metastatic breast cancer is treated today, the most recent significant research findings that may influence your care, and promising clinical trials underway. During part two, Dr. Fuqua will explore how her lab research may help us learn what drives some hormone receptor-positive breast cancers to return, what makes them become resistant to treatment, and what researchers hope they can do to make these cancers sensitive to hormone-targeting therapy again.
Просмотров: 325 Living Beyond Breast Cancer
Dr. Callahan on Endocrine Therapy in Patients With ER-Positive Breast Cancer
 
01:54
Rena D. Callahan, MD, assistant clinical professor of medicine, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses the use of endocrine therapy in patients with estrogen receptor (ER)-positive breast cancer.
Просмотров: 60 OncLiveTV
BREAST CANCER ,Plant Based Diet May Convert Aggressive Type To Treatable One
 
11:13
BREAST CANCER ,Plant Based Diet May Convert Aggressive Type To Treatable One. Researchers at the University of Alabama at Birmingham have found a dietary combination that transforms the most lethal of all breast cancers into a highly treatable breast cancer. Specifically, scientists involved in the Scientific Reports study say a particular plant-based diet may be the key. Trygve Tollefsbol, Ph.D., D.O., professor of biology in the College of Arts and Sciences and senior scientist with the Comprehensive Cancer Center as well as Yuanyuan Li, M.D., Ph.D., a research assistant professor of biology, use epigenetics — the study of biological mechanisms that will switch genes on and off — as a mechanism to identify ways we can change human gene expressions in fatal diseases, including breast cancer. All breast cancers are either estrogen receptor-positive or estrogen receptor-negative. The tumors in estrogen receptor, or ER, negative breast cancer are much less likely to respond to hormone therapy than are tumors that are ER-positive, which means that ER-negative breast cancers are typically very aggressive. “Unfortunately, there are few options for women who develop ER-negative breast cancer,” Tollefsbol said. “Because of the poor prognosis this type of cancer carries, new advances in prevention and treatment for ER-negative breast cancer have particular significance.” With that in mind, Tollefsbol and fellow researchers set out to further research how scientists can efficiently neutralize mechanisms that lead to, and worsen, ER-negative cancers. Up until this time, conventional cancer prevention has focused primarily on single chemopreventive compounds. “One reason many in the field shy away from combining two or more compounds at a time for treatment research is the fear of adverse effects and potential interactions that are unknown,” Tollefsbol said. “To overcome that concern, we chose compounds that we felt confident would interact well together, because they have similar favorable biological effects but still have different mechanisms for carrying out these effects that would not interfere with one another.” Tollefsbol and his team identified two compounds in common foods that are known to have success in cancer prevention and that could potentially be combined to successfully “turn on” the ER gene in ER-negative breast cancer so that the cancer could be treated with estrogen receptor inhibitors such as tamoxifen. “One way we can use epigenetics as a powerful tool to fight cancer is through compounds found in our everyday diet,” Tollefsbol said. “Vegetables, for example, are filled with these types of compounds. Your mother always told you to eat your vegetables, and science now tells us she was right.” Another compound found in green tea has been shown to stimulate epigenetic changes in cancerous genes, according to prior studies from Tollefsbol’s lab. These compounds, used in the right way, can help modulate gene expression aberrations that are contributing to the disease. The researchers found that a combination of dietary plant-derived compounds consisting of sulforaphane from cruciferous vegetables such as broccoli sprouts, along with polyphenols from green tea, is successful in preventing and treating ER-negative breast cancer in mice that are genetically programed to develop ER-negative breast cancer at high rates. Further investigation revealed that the mechanism for the efficacy of these two dietary compounds involved epigenetic changes induced in the ER gene regulatory region. With the combined dietary treatment the researchers administered, the tumors in the mice were converted from ER-negative to ER-positive cancers. This rendered the breast cancer easily treatable with tamoxifen, an estrogen receptor inhibitor. “The results of this research provide a novel approach to preventing and treating ER-negative breast cancer, which currently takes hundreds of thousands of lives worldwide,” said Li. “The next step would be to move this to clinical trial, and to eventually be able to provide more effective treatment options for women either predisposed to or afflicted with this deadly disease.”
Просмотров: 5426 Be Healthy
PALOMA-3: Palbociclib plus fulvestrant in hormone receptor-positive advanced breast cancer
 
03:02
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Lisa A. Carey, MD, of the University of North Carolina, Chapel Hill, NC, discusses the results of the double-blind, phase 3 PALOMA-3 trial of fulvestrant with or without palbociclib in pre- and post-menopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy.
Просмотров: 540 European Medical Group
Future Directions: CDK4/6 Inhibitors in Breast Cancer
 
04:52
Sara Hurvitz, MD, and Hope S. Rugo, MD, discuss the potential use of CDK4/6 inhibitors in the operable setting, looking at adjuvant and neoadjuvant use in high-risk estrogen receptor-positive metastatic breast cancer.
Просмотров: 333 OncLiveTV
Letrozole vs observation for HR positive breast cancer
 
04:33
Visit http://www.ecancer.org for more Dr Zdenkowski (University of Newcastle, Newcastle, Australia) talks to ecancertv at ASCO 2015 about the final analysis of a randomised comparison of letrozole versus observation as late reintroduction of adjuvant endocrine therapy (AET) for postmenopausal women with hormone receptor positive breast cancer after completion of prior AET.
Просмотров: 871 ecancer